NCT02905227View on ClinicalTrials.gov

A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Migraine
Interventions
DRUG

CVT-427 (zolmitriptan inhalation powder)

Each subject received 2 self-administered doses of 3.0 mg CVT-427 (zolmitriptan inhalation powder), 2 hours apart.

Trial Locations (3)

68502

Site #102, Lincoln

75247

Site #101, Dallas

02747

Site #103, North Dartmouth

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY